Demonstration of biological activity of prolactin molecular weight variants in human sera

M. D. Whitaker, G. G. Klee, P. C. Kao, R. V. Randall, D. W. Heser

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Three immunoreactive forms of PRL, separated by Sephadex G-100 column chromatography, were identified in serum samples from 10 normal subjects and 7 patients with PRL-secreting pituitary tumors. Fractions eluted from the column were assayed for bioactivity by using a sensitive bioassay with the Nb2 cell line. Three molecular weight variants of PRL were identified in normal subjects. In samples from 9 of the 10 normal subjects, 80.1 ± 3.6% (mean ± SEM) of the total bioactivity eluted in a peak corresponding to a PRL monomer (peak III) with a mol wt of approximately 24,000, 18.3 ± 3.7% eluted in a peak with a mol wt of approximately 56,000 (peak II), and 1.6 ± 1.1% of the biological activity was in the void volume (peak I). In the 10th normal sample, 65% of the total bioactivity was in the void volume (peak I), 31% was in peak III, and 4% was in peak II. Samples from the patients had 3.6 ± 0.7% of the total bioactivity in peak I, 9.3 ± 1.0% in peak II, and 87.0 ± 1.1% in peak III, percentages not significantly different from normal. For comparison with bioassay, RIA measurement of PRL was performed on all fractions of 6 samples (3 normal subjects and 3 tumor patients). Good correlation was found between RIA and bioassay measurements under each of the 3 peaks identified. We conclude that 1) in sera from normal subjects, 3 molecular weight variants of PRL have biological activity; 2) in patients with PRL-secreting tumors, secretion of biologically active PRL molecular weight variants is not proportionately different from that in normal subjects; and 3) the results of the Nb2 PRL bioassay correlate well with PRL levels determined by RIA for each of 3 molecular weight variants identified.

Original languageEnglish (US)
Pages (from-to)826-830
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume58
Issue number5
StatePublished - 1984

Fingerprint

Bioactivity
Biological Assay
Prolactin
Demonstrations
Bioassay
Molecular Weight
Molecular weight
Serum
Tumors
Pituitary Neoplasms
Chromatography
Neoplasms
Column chromatography
Cell Line
Monomers
Cells
Scanning electron microscopy

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Whitaker, M. D., Klee, G. G., Kao, P. C., Randall, R. V., & Heser, D. W. (1984). Demonstration of biological activity of prolactin molecular weight variants in human sera. Journal of Clinical Endocrinology and Metabolism, 58(5), 826-830.

Demonstration of biological activity of prolactin molecular weight variants in human sera. / Whitaker, M. D.; Klee, G. G.; Kao, P. C.; Randall, R. V.; Heser, D. W.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 58, No. 5, 1984, p. 826-830.

Research output: Contribution to journalArticle

Whitaker, MD, Klee, GG, Kao, PC, Randall, RV & Heser, DW 1984, 'Demonstration of biological activity of prolactin molecular weight variants in human sera', Journal of Clinical Endocrinology and Metabolism, vol. 58, no. 5, pp. 826-830.
Whitaker, M. D. ; Klee, G. G. ; Kao, P. C. ; Randall, R. V. ; Heser, D. W. / Demonstration of biological activity of prolactin molecular weight variants in human sera. In: Journal of Clinical Endocrinology and Metabolism. 1984 ; Vol. 58, No. 5. pp. 826-830.
@article{33c0065d807d427ea9c655c5e63430de,
title = "Demonstration of biological activity of prolactin molecular weight variants in human sera",
abstract = "Three immunoreactive forms of PRL, separated by Sephadex G-100 column chromatography, were identified in serum samples from 10 normal subjects and 7 patients with PRL-secreting pituitary tumors. Fractions eluted from the column were assayed for bioactivity by using a sensitive bioassay with the Nb2 cell line. Three molecular weight variants of PRL were identified in normal subjects. In samples from 9 of the 10 normal subjects, 80.1 ± 3.6{\%} (mean ± SEM) of the total bioactivity eluted in a peak corresponding to a PRL monomer (peak III) with a mol wt of approximately 24,000, 18.3 ± 3.7{\%} eluted in a peak with a mol wt of approximately 56,000 (peak II), and 1.6 ± 1.1{\%} of the biological activity was in the void volume (peak I). In the 10th normal sample, 65{\%} of the total bioactivity was in the void volume (peak I), 31{\%} was in peak III, and 4{\%} was in peak II. Samples from the patients had 3.6 ± 0.7{\%} of the total bioactivity in peak I, 9.3 ± 1.0{\%} in peak II, and 87.0 ± 1.1{\%} in peak III, percentages not significantly different from normal. For comparison with bioassay, RIA measurement of PRL was performed on all fractions of 6 samples (3 normal subjects and 3 tumor patients). Good correlation was found between RIA and bioassay measurements under each of the 3 peaks identified. We conclude that 1) in sera from normal subjects, 3 molecular weight variants of PRL have biological activity; 2) in patients with PRL-secreting tumors, secretion of biologically active PRL molecular weight variants is not proportionately different from that in normal subjects; and 3) the results of the Nb2 PRL bioassay correlate well with PRL levels determined by RIA for each of 3 molecular weight variants identified.",
author = "Whitaker, {M. D.} and Klee, {G. G.} and Kao, {P. C.} and Randall, {R. V.} and Heser, {D. W.}",
year = "1984",
language = "English (US)",
volume = "58",
pages = "826--830",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Demonstration of biological activity of prolactin molecular weight variants in human sera

AU - Whitaker, M. D.

AU - Klee, G. G.

AU - Kao, P. C.

AU - Randall, R. V.

AU - Heser, D. W.

PY - 1984

Y1 - 1984

N2 - Three immunoreactive forms of PRL, separated by Sephadex G-100 column chromatography, were identified in serum samples from 10 normal subjects and 7 patients with PRL-secreting pituitary tumors. Fractions eluted from the column were assayed for bioactivity by using a sensitive bioassay with the Nb2 cell line. Three molecular weight variants of PRL were identified in normal subjects. In samples from 9 of the 10 normal subjects, 80.1 ± 3.6% (mean ± SEM) of the total bioactivity eluted in a peak corresponding to a PRL monomer (peak III) with a mol wt of approximately 24,000, 18.3 ± 3.7% eluted in a peak with a mol wt of approximately 56,000 (peak II), and 1.6 ± 1.1% of the biological activity was in the void volume (peak I). In the 10th normal sample, 65% of the total bioactivity was in the void volume (peak I), 31% was in peak III, and 4% was in peak II. Samples from the patients had 3.6 ± 0.7% of the total bioactivity in peak I, 9.3 ± 1.0% in peak II, and 87.0 ± 1.1% in peak III, percentages not significantly different from normal. For comparison with bioassay, RIA measurement of PRL was performed on all fractions of 6 samples (3 normal subjects and 3 tumor patients). Good correlation was found between RIA and bioassay measurements under each of the 3 peaks identified. We conclude that 1) in sera from normal subjects, 3 molecular weight variants of PRL have biological activity; 2) in patients with PRL-secreting tumors, secretion of biologically active PRL molecular weight variants is not proportionately different from that in normal subjects; and 3) the results of the Nb2 PRL bioassay correlate well with PRL levels determined by RIA for each of 3 molecular weight variants identified.

AB - Three immunoreactive forms of PRL, separated by Sephadex G-100 column chromatography, were identified in serum samples from 10 normal subjects and 7 patients with PRL-secreting pituitary tumors. Fractions eluted from the column were assayed for bioactivity by using a sensitive bioassay with the Nb2 cell line. Three molecular weight variants of PRL were identified in normal subjects. In samples from 9 of the 10 normal subjects, 80.1 ± 3.6% (mean ± SEM) of the total bioactivity eluted in a peak corresponding to a PRL monomer (peak III) with a mol wt of approximately 24,000, 18.3 ± 3.7% eluted in a peak with a mol wt of approximately 56,000 (peak II), and 1.6 ± 1.1% of the biological activity was in the void volume (peak I). In the 10th normal sample, 65% of the total bioactivity was in the void volume (peak I), 31% was in peak III, and 4% was in peak II. Samples from the patients had 3.6 ± 0.7% of the total bioactivity in peak I, 9.3 ± 1.0% in peak II, and 87.0 ± 1.1% in peak III, percentages not significantly different from normal. For comparison with bioassay, RIA measurement of PRL was performed on all fractions of 6 samples (3 normal subjects and 3 tumor patients). Good correlation was found between RIA and bioassay measurements under each of the 3 peaks identified. We conclude that 1) in sera from normal subjects, 3 molecular weight variants of PRL have biological activity; 2) in patients with PRL-secreting tumors, secretion of biologically active PRL molecular weight variants is not proportionately different from that in normal subjects; and 3) the results of the Nb2 PRL bioassay correlate well with PRL levels determined by RIA for each of 3 molecular weight variants identified.

UR - http://www.scopus.com/inward/record.url?scp=0021240393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021240393&partnerID=8YFLogxK

M3 - Article

C2 - 6707188

AN - SCOPUS:0021240393

VL - 58

SP - 826

EP - 830

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -